Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements.
ALK
ALKAL2
Augmentor
FAM150
MYCN
neuroblastoma
Journal
Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
revised:
15
07
2019
received:
10
01
2019
accepted:
15
07
2019
pubmed:
25
7
2019
medline:
25
7
2019
entrez:
25
7
2019
Statut:
ppublish
Résumé
Gain of chromosome arm 2p is a previously described entity in neuroblastoma (NB). This genomic address is home to two important oncogenes in NB-MYCN and anaplastic lymphoma kinase (ALK). MYCN amplification is a critical prognostic factor coupled with poor prognosis in NB. Mutation of the ALK receptor tyrosine kinase has been described in both somatic and familial NB. Here, ALK activation occurs in the context of the full-length receptor, exemplified by activating point mutations in NB. ALK overexpression and activation, in the absence of genetic mutation has also been described in NB. In addition, the recently identified ALK ligand ALKAL2 (previously described as FAM150B and AUGα) is also found on the distal portion of 2p, at 2p25. Here we analyze 356 NB tumor samples and discuss observations indicating that gain of 2p has implications for the development of NB. Finally, we put forward the hypothesis that the effect of 2p gain may result from a combination of MYCN, ALK, and the ALK ligand ALKAL2.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50-57Subventions
Organisme : Lions Cancerfond Väst
ID : TM
Organisme : Barncancerfonden
ID : BH 17/110
Organisme : Barncancerfonden
ID : RHP 15/0096
Organisme : Barncancerfonden
ID : SF 2014/0064
Organisme : Barncancerfonden
ID : SF 2015/0061
Organisme : Barncancerfonden
ID : TM 2016/0147
Organisme : Barncancerfonden
ID : TM 2017/0166
Organisme : Cancerfonden
ID : BH 18-651
Organisme : Cancerfonden
ID : RHP 18-0729
Organisme : Cancerfonden
ID : RHP 18-0834
Organisme : Cancerfonden
ID : TM 18-1711
Organisme : Göran Gustafssons Stiftelse för Naturvetenskaplig och Medicinsk Forskning
ID : RHP2016
Organisme : LUA/ALF
ID : TM ALFGBG-447171
Organisme : Stiftelsen för Strategisk Forskning
ID : TM/RP/BH/PK RB13-0204
Organisme : Vetenskapsrådet
ID : BH 521-2017-1324
Organisme : Vetenskapsrådet
ID : RHP 2015-04466
Organisme : Vetenskapsrådet
ID : TM/SF; 2014-3031
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106-2120.
Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930-935.
Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455(7215):967-970.
Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416(2):153-159.
Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455(7215):971-974.
George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975-978.
Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013;13(10):685-700.
Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol. 2000;156(5):1711-1721.
Dirks WG, Fahnrich S, Lis Y, Becker E, MacLeod RA, Drexler HG. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer. 2002;100(1):49-56.
Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277(39):35990-35998.
Miyake I, Hakomori Y, Shinohara A, et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene. 2002;21(38):5823-5834.
Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol. 2005;167(1):213-222.
McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68(9):3389-3395.
Caren H, Erichsen J, Olsson L, et al. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics. 2008;9:353.
De Brouwer S, De Preter K, Kumps C, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res. 2010;16(17):4353-4362.
Javanmardi N, Fransson S, Djos A, et al. Low frequency ALK hotspots mutations in neuroblastoma tumours detected by ultra-deep sequencing: implications for ALK inhibitor treatment. Sci Rep. 2019;9(1):2199.
Duijkers FA, Gaal J, Meijerink JP, et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol. 2012;180(3):1223-1231.
Wang M, Zhou C, Sun Q, et al. ALK amplification and protein expression predict inferior prognosis in neuroblastomas. Exp Mol Pathol. 2013;95(2):124-130.
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121-1124.
Schonherr C, Ruuth K, Kamaraj S, et al. Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene. 2012;31(50):5193-5200.
Hasan MK, Nafady A, Takatori A, et al. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Sci Rep. 2013;3:3450.
Liu Z, Thiele CJ. ALK and MYCN: when two oncogenes are better than one. Cancer Cell. 2012;21(3):325-326.
Zhu S, Lee JS, Guo F, et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012;21(3):362-373.
Berry T, Luther W, Bhatnagar N, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012;22(1):117-130.
Heukamp LC, Thor T, Schramm A, et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med. 2012;4(141):141ra191.
Guan J, Umapathy G, Yamazaki Y, et al. FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. Elife. 2015;4:e09811.
Reshetnyak AV, Murray PB, Shi X, et al. Augmentor alpha and beta (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: hierarchy and specificity of ligand-receptor interactions. Proc Natl Acad Sci U S A. 2015;112(52):15862-15867.
Zhang H, Pao LI, Zhou A, et al. Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome. Proc Natl Acad Sci U S A. 2014;111(44):15741-15745.
Mo ES, Cheng QN, Reshetnyak AV, Schlessinger J, Nicoli S. Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk. Proc Natl Acad Sci U S A. 2017;114(45):12027-12032.
Fadeev A, Mendoza-Garcia P, Irion U, et al. ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells. Proc Natl Acad Sci U S A. 2018;115:E630-E638.
Caren H, Kryh H, Nethander M, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010;107(9):4323-4328.
Umapathy G, Guan J, Gustafsson DE, et al. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Sci Signal. 2017;10(507):eaam7550.
Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27(7):1026-1033.
Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483(7391):589-593.
Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279-284.
Sausen M, Leary RJ, Jones S, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013;45(1):12-17.
Peifer M, Hertwig F, Roels F, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526(7575):700-704.
Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26(5):682-694.
Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004;64(24):8816-8820.
Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307(10):1062-1071.
Valentijn LJ, Koster J, Zwijnenburg DA, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015;47(12):1411-1414.
Schleiermacher G, Javanmardi N, Bernard V, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol. 2014;32(25):2727-2734.
Torres EM, Williams BR, Amon A. Aneuploidy: cells losing their balance. Genetics. 2008;179(2):737-746.
Williams BR, Prabhu VR, Hunter KE, et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science. 2008;322(5902):703-709.
Kim EK, Kim S. ALK gene copy number gain and immunohistochemical expression status using three antibodies in neuroblastoma. Pediatr Dev Pathol. 2017;20(2):133-141.
Defferrari R, Tonini GP, Conte M, et al. Concomitant DDX1 and MYCN gain in neuroblastoma. Cancer Lett. 2007;256(1):56-63.
Weber A, Imisch P, Bergmann E, Christiansen H. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol. 2004;22(13):2681-2690.
De Preter K, Speleman F, Combaret V, et al. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol. 2005;23(13):3167-3168.
Ambros IM, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol. 2003;21(11):2077-2084.
Levan G, Mandahl N, Bregula U, Klein G, Levan A. Double minute chromosomes are not centromeric regions of the host chromosomes. Hereditas. 1976;83(1):83-90.
Levan A, Levan G. Have double minutes functioning centromeres? Hereditas. 1978;88(1):81-92.
Schwab M, Ramsay G, Alitalo K, et al. Amplification and enhanced expression of the c-myc oncogene in mouse SEWA tumour cells. Nature. 1985;315(6017):345-347.
Jeison M, Ash S, Halevy-Berko G, et al. 2p24 gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics. Am J Pathol. 2010;176(6):2616-2625.
Subramaniam MM, Piqueras M, Navarro S, Noguera R. Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas. Hum Pathol. 2009;40(11):1638-1642.
Stock C, Bozsaky E, Watzinger F, et al. Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization. Am J Pathol. 2008;172(1):203-214.
Say B, Carpenter NJ, Giacoia G, Jegathesan S. Agenesis of the lung associated with a chromosome abnormality (46,XX,2p+). J Med Genet. 1980;17(6):477-478.
Patel JS, Pearson J, Willatt L, Andrews T, Beach R, Green A. Germline duplication of chromosome 2p and neuroblastoma. J Med Genet. 1997;34(11):949-951.
Dowa Y, Yamamoto T, Abe Y, et al. Congenital neuroblastoma in a patient with partial trisomy of 2p. J Pediatr Hematol Oncol. 2006;28(6):379-382.
Nagano H, Kano Y, Kobuchi S, Kajitani T. A case of partial 2p trisomy with neuroblastoma. Jinrui Idengaku Zasshi. 1980;25(1):39-45.
Morgenstern DA, Soh SY, Stavropoulos DJ, et al. Metachronous neuroblastoma in an infant with germline translocation resulting in partial trisomy 2p: a role for ALK? J Pediatr Hematol Oncol. 2014;36(3):e193-e196.
Martinsson T, Eriksson T, Abrahamsson J, et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res. 2011;71(1):98-105.